Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.
External link for Earli Inc.
1400 Bridge Pkwy
Suite 201
Redwood City, California 94065, US
Meet Earli’s Chief Scientific Officer, Dr. David Suhy.
A great story about my co-founder David Suhy who has built a team of top scientists and experts with me at Earli Inc. to “turn cancer against itself” by a completely new approach: by *forcing* cancer to reveal, and ultimately also kill, itself. David is Earli’s Chief Scientific Officer, and he has an amazing story to tell. #cancer #startup #earlydetection #biotech https://lnkd.in/guJYzQSP
Earli on a top German technology podcast about how to detect and treat cancer much earlier, and what it takes to build a biotech startup.
Für alle, die an der neuesten Methode interessiert sind, Krebs ganz früh zu erkennen und zu behandeln, und für alle, die mal hören wollen, wie man als Nichtbiologe ein Biotechstartup aufbaut, haben wir einen Podcast mit der deutschen EUR 1 Mrd-Sprunginnovations-Agentur SPRIND aufgenommen: “Wie lässt sich Krebs deutlich früher erkennen? Könnten künstliche Biomarker das Immunsystem auf Krebzellen hetzen? Und warum ist es in den USA so viel einfacher, ein Biotech-Unternehmen zu gründen? Unser Host Thomas Ramge spricht mit dem deutsch-amerikanischen Gründer und Investor Cyriac Roeding.” https://lnkd.in/dVrkEN8G #krebs #krebsforschung #startups #biotech #entrepreneurship